S&P/ASX 200 Pre Market News
Rask Invest Research Team
May 17, 2018
Futures contracts for the S&P/ASX 200 (INDEXASX: XJO)(ASX: XJO) index
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Futures contracts for the S&P/ASX 200 (INDEXASX: XJO)(ASX: XJO) index
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX:
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX:
The S&P/ASX 200 (INDEXASX: XJO) (^AXJO) and All Ordinaries (INDEXASX:
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX:
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX:
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX:
The Australian share market, or S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO), is expected
CSL Limited (ASX:CSL) tried its best to inject some enthusiasm
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
